-
Oral semaglutide 25 mg demonstrated significantly greater mean weight loss than orforglipron 36 mg in a population-adjusted indirect treatment comparison (ITC) using data from the OASIS 4 and ATTAIN-1 clinical trials1
-
Treatment with orforglipron 36 mg was associated with ~14 times higher odds of stopping medication due to GI adverse events versus oral semaglutide 25 mg in the ITC1
-
In a separate patient preference study, 84% of survey respondents favored the treatment profile similar to oral semaglutide 25 mg compared to that similar to orforglipron2
23 Likes